ArticleThe American journal of case reports2026
Coexistence of Multiple Myeloma, Mast Cell Hyperplasia, and Low-Level Myeloid Blastocytosis: A Report of a Rare Case.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Mast cell hyperplasia can present as systemic mastocytosis (SM) or reactive mast cell hyperplasia. Distinguishing between these 2 diseases is a critical challenge. Here, we report a rare case of concurrent mast cell hyperplasia, multiple myeloma (MM), and low-level myeloid blastocytosis. The potential mechanisms underlying the coexistence of the aforementioned 3 diseases were also analyzed. CASE REPORT A patient with muscle pain was initially diagnosed with monoclonal gammopathy of undetermined significance (MGUS). Three years later, she progressively developed pancytopenia and renal function impairment. Three populations of abnormal cells were found in the bone marrow (myeloma cells 10.5%, myeloid blasts 0.18%, and mast cells 10%). Bone marrow biopsy (BMB) showed a single focal mast cell aggregate (>15 cells) with no multifocal dense infiltrates. Tryptase testing and KIT D816V mutation analysis results were negative. CD25 and additional KIT gene sequencing were not performed. Finally, she was diagnosed with multiple myeloma (MM), mast cell hyperplasia, and low-level myeloid blastocytosis. CONCLUSIONS This association among MM, mast cell hyperplasia, and low-level myeloid blastocytosis could either arise from abnormal stem cells of a common origin or result from one disease indirectly inducing or accelerating the progression of the other. Comprehensive immunophenotyping (including CD117, CD2, CD30, and CD25) and KIT mutation analysis are necessary to differentiate reactive mast cell hyperplasia from both systemic mastocytosis (SM) and SM with an associated hematologic neoplasm (SM-AHN). Positive expression of CD2, CD25, or CD30 together with KIT mutation may indicate SM or SM-AHN, and additional diagnostic criteria are required to confirm the diagnosis. If all the above test results are negative, reactive mast cell hyperplasia can be considered. More mechanistic evidence and similar cases are needed to better understand complex multilineage dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.